(Q39520772)

12 September 2017

title

In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein (English)

1 reference

12 September 2017

1 reference

3

1 reference

12 September 2017

4

1 reference

12 September 2017

Chunbo Zhang

1

1 reference

12 September 2017

Zhong Zuo

series ordinal

2

1 reference

12 September 2017

publication date

21 June 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

52

1 reference

12 September 2017

issue

10

1 reference

12 September 2017

page(s)

1894-1904

1 reference

Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Key factors in the discovery and development of new antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Membrane transporters in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

A primer on the mechanics of P-glycoprotein the multidrug transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Antiepileptic drugs in schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

A computational quantitative structure-activity relationship study of carbamate anticonvulsants using quantum pharmacological methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Early identification of refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Potential role of drug transporters in the pathogenesis of medically intractable epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Emerging drugs for epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Drug resistance in brain diseases and the role of drug efflux transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Several major antiepileptic drugs are substrates for human P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

21 January 2018

Eslicarbazepine acetate.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Carbamazepine is not a substrate for P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

P-glycoprotein recognition of substrates and circumvention through rational drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Clinical aspects and biological bases of drug-resistant epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

MDR1 gene expression in brain of patients with medically intractable epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Application and limitation of inhibitors in drug-transporter interactions studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Inhibition of P-glycoprotein by newer antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Interaction of antiepileptic drugs with human P-glycoprotein in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

Carbamazepine poisoning: elimination kinetics and quantitative relationship with carbamazepine 10,11-epoxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03140.X

10.1111/J.1528-1167.2011.03140.X

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference